Mirati Therapeutics, Inc.
MRTXDrugs in Pipeline
14
Phase 3 Programs
7
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
MRTX849
Advanced Cancer
Docetaxel
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Adagrasib
Carcinoma, Non-Small-Cell Lung
Pembrolizumab
Advanced Non-Small Cell Lung Cancer
Cetuximab
Advanced Colorectal Cancer
Enfortumab Vedotin-Ejfv
Advanced or Metastatic Solid Malignancies
Sitravatinib
Clear Cell Renal Cell Carcinoma
Pemetrexed
Solid Tumors
Adagrasib oral dose of 400 mg twice daily tablets
Advanced NSCLC
MGCD265
Non-Small Cell Lung Cancer
Gemcitabine
Tumors
MRTX0902
Solid Tumor
Mocetinostat
Myelodysplastic Syndrome
MGCD0103
Lymphocytic Leukemia, Chronic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MRTX849 | Phase 3 | Advanced Cancer | - | - |
Docetaxel | Phase 3 | Metastatic Non-Squamous Non-Small Cell Lung Cancer | - | - |
Adagrasib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Pembrolizumab | Phase 3 | Advanced Non-Small Cell Lung Cancer | - | - |
Cetuximab | Phase 3 | Advanced Colorectal Cancer | - | - |
Enfortumab Vedotin-Ejfv | Phase 3 | Advanced or Metastatic Solid Malignancies | - | - |
Sitravatinib | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
Pemetrexed | Phase 2 | Solid Tumors | - | - |
Adagrasib oral dose of 400 mg twice daily tablets | Phase 2 | Advanced NSCLC | - | - |
MGCD265 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Gemcitabine | Phase 2 | Tumors | - | - |
MRTX0902 | Phase 2 | Solid Tumor | - | - |
Mocetinostat | Phase 2 | Myelodysplastic Syndrome | - | - |
MGCD0103 | Phase 2 | Lymphocytic Leukemia, Chronic | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Mirati Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 14 drug candidates in Mirati Therapeutics, Inc.'s (MRTX) pipeline across Phase 3, Phase 2. Its lead program is MRTX849 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Mirati Therapeutics, Inc.'s next FDA catalyst?→
Mirati Therapeutics, Inc.'s (MRTX) next tracked catalyst is a Phase 2 expected September 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MRTX biotech catalysts?→
Add MRTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Mirati Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.